886 related articles for article (PubMed ID: 8008069)
1. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
Brown EJ; Albers MW; Shin TB; Ichikawa K; Keith CT; Lane WS; Schreiber SL
Nature; 1994 Jun; 369(6483):756-8. PubMed ID: 8008069
[TBL] [Abstract][Full Text] [Related]
2. Control of p70 s6 kinase by kinase activity of FRAP in vivo.
Brown EJ; Beal PA; Keith CT; Chen J; Shin TB; Schreiber SL
Nature; 1995 Oct; 377(6548):441-6. PubMed ID: 7566123
[TBL] [Abstract][Full Text] [Related]
3. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
Sabatini DM; Erdjument-Bromage H; Lui M; Tempst P; Snyder SH
Cell; 1994 Jul; 78(1):35-43. PubMed ID: 7518356
[TBL] [Abstract][Full Text] [Related]
4. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
Sabers CJ; Martin MM; Brunn GJ; Williams JM; Dumont FJ; Wiederrecht G; Abraham RT
J Biol Chem; 1995 Jan; 270(2):815-22. PubMed ID: 7822316
[TBL] [Abstract][Full Text] [Related]
5. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
Fruman DA; Wood MA; Gjertson CK; Katz HR; Burakoff SJ; Bierer BE
Eur J Immunol; 1995 Feb; 25(2):563-71. PubMed ID: 7533090
[TBL] [Abstract][Full Text] [Related]
6. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
Lorenz MC; Heitman J
J Biol Chem; 1995 Nov; 270(46):27531-7. PubMed ID: 7499212
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin resistance in ataxia-telangiectasia.
Beamish H; Williams R; Chen P; Khanna KK; Hobson K; Watters D; Shiloh Y; Lavin M
Oncogene; 1996 Sep; 13(5):963-70. PubMed ID: 8806686
[TBL] [Abstract][Full Text] [Related]
8. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
Cafferkey R; Young PR; McLaughlin MM; Bergsma DJ; Koltin Y; Sathe GM; Faucette L; Eng WK; Johnson RK; Livi GP
Mol Cell Biol; 1993 Oct; 13(10):6012-23. PubMed ID: 8413204
[TBL] [Abstract][Full Text] [Related]
9. Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization.
Moore PA; Rosen CA; Carter KC
Genomics; 1996 Apr; 33(2):331-2. PubMed ID: 8660990
[No Abstract] [Full Text] [Related]
10. Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells.
Metcalfe SM; Canman CE; Milner J; Morris RE; Goldman S; Kastan MB
Oncogene; 1997 Oct; 15(14):1635-42. PubMed ID: 9349496
[TBL] [Abstract][Full Text] [Related]
11. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.
Zheng XF; Florentino D; Chen J; Crabtree GR; Schreiber SL
Cell; 1995 Jul; 82(1):121-30. PubMed ID: 7606777
[TBL] [Abstract][Full Text] [Related]
12. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.
Cardenas ME; Heitman J
EMBO J; 1995 Dec; 14(23):5892-907. PubMed ID: 8846782
[TBL] [Abstract][Full Text] [Related]
13. The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease.
Schmidt A; Beck T; Koller A; Kunz J; Hall MN
EMBO J; 1998 Dec; 17(23):6924-31. PubMed ID: 9843498
[TBL] [Abstract][Full Text] [Related]
14. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.
Stan R; McLaughlin MM; Cafferkey R; Johnson RK; Rosenberg M; Livi GP
J Biol Chem; 1994 Dec; 269(51):32027-30. PubMed ID: 7528205
[TBL] [Abstract][Full Text] [Related]
15. The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity.
Sabatini DM; Pierchala BA; Barrow RK; Schell MJ; Snyder SH
J Biol Chem; 1995 Sep; 270(36):20875-8. PubMed ID: 7673106
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.
Kuo CJ; Chung J; Fiorentino DF; Flanagan WM; Blenis J; Crabtree GR
Nature; 1992 Jul; 358(6381):70-3. PubMed ID: 1614535
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.
Alarcon CM; Heitman J; Cardenas ME
Mol Biol Cell; 1999 Aug; 10(8):2531-46. PubMed ID: 10436010
[TBL] [Abstract][Full Text] [Related]
18. Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.
Alarcon CM; Cardenas ME; Heitman J
Genes Dev; 1996 Feb; 10(3):279-88. PubMed ID: 8595879
[TBL] [Abstract][Full Text] [Related]
19. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.
Chen J; Zheng XF; Brown EJ; Schreiber SL
Proc Natl Acad Sci U S A; 1995 May; 92(11):4947-51. PubMed ID: 7539137
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.
Wiederrecht GJ; Sabers CJ; Brunn GJ; Martin MM; Dumont FJ; Abraham RT
Prog Cell Cycle Res; 1995; 1():53-71. PubMed ID: 9552353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
